Letizia Porcelli
Overview
Explore the profile of Letizia Porcelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azzariti A, De Summa S, Marvulli T, De Risi I, De Palma G, Di Fonte R, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):40.
PMID: 39910579
Background: Despite the high response rate to PD-1 blockade therapy in metastatic melanoma (MM) patients, a significant proportion of patients do not respond. Identifying biomarkers to predict patient response is...
2.
Serrati S, Zerlotin R, Manganelli M, Di Fonte R, Dicarlo M, Oranger A, et al.
Int J Mol Sci
. 2025 Jan;
26(2).
PMID: 39859367
Irisin is a newly discovered 12 kDa messenger protein involved in energy metabolism. Irisin affects signaling pathways in several types of cancer; however, the role of irisin in metastatic melanoma...
3.
Arduino I, Di Fonte R, Sommonte F, Lopedota A, Porcelli L, Li J, et al.
Int J Nanomedicine
. 2024 Dec;
19:13217-13233.
PMID: 39679250
Introduction: The treatment of glioblastoma is hindered by the blood-brain barrier (BBB) and rapid drug clearance by the immune system. To address these challenges, we propose a novel drug delivery...
4.
Fasano R, Serrati S, Rafaschieri T, Longo V, Di Fonte R, Porcelli L, et al.
Biomolecules
. 2024 Apr;
14(4).
PMID: 38672414
Small-cell lung cancer (SCLC) cases represent approximately 15% of all lung cancer cases, remaining a recalcitrant malignancy with poor survival and few treatment options. In the last few years, the...
5.
Arduino I, Di Fonte R, Tiboni M, Porcelli L, Serrati S, Fondaj D, et al.
Int J Pharm
. 2023 Dec;
650:123697.
PMID: 38081557
Optimizing current therapies is among next steps in metastatic melanoma (MM) treatment landscape. The innovation of this study is the design of production process by microfluidics of cell membrane (CM)-modified...
6.
Serrati S, Di Fonte R, Porcelli L, De Summa S, De Risi I, Fucci L, et al.
J Exp Clin Cancer Res
. 2023 Sep;
42(1):251.
PMID: 37759291
Background: Clinical drawback in checkpoint inhibitors immunotherapy (ICI) of metastatic melanoma (MM) is monitoring clinical benefit. Soluble forms of PD1(sPD1) and PD-L1(sPD-L1) and extracellular vesicles (EVs) expressing PD1 and PD-L1...
7.
Di Fonte R, Strippoli S, Garofoli M, Cormio G, Serrati S, Loizzi V, et al.
Front Cell Dev Biol
. 2023 Jun;
11:1178316.
PMID: 37384250
Cervical cancer (CC) is characterized by genomic alterations in DNA repair genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs), such as trabectedin. Hence, we evaluated the...
8.
Doronzo A, Porcelli L, Marziliano D, Inglese G, Argentiero A, Azzariti A, et al.
Medicina (Kaunas)
. 2023 May;
59(5).
PMID: 37241104
: Over the past few decades, there has been much debate and research into the link between alcohol consumption and the development and progression of pancreatic ductal adenocarcinoma (PDAC). :...
9.
Porcelli L, Di Fonte R, Pierri C, Fucci L, Saponaro C, Armenio A, et al.
Pharmacol Res
. 2022 Jun;
182:106323.
PMID: 35752358
The V600E mutation in BRAF is associated with increased phosphorylation of Erk1/2 and high sensitivity to BRAFi/MEKi combination in metastatic melanoma. In very few patients, a tandem mutation in BRAF,...
10.
Serrati S, Guida M, Di Fonte R, De Summa S, Strippoli S, Iacobazzi R, et al.
Mol Cancer
. 2022 Jan;
21(1):20.
PMID: 35042524
Background: The immunotherapy with immune checkpoints inhibitors (ICI) has changed the life expectancy in metastatic melanoma (MM) patients. Nevertheless, several patients do not respond hence, the identification and validation of...